CR9298A - Marcadores farmacogenomicos para el pronostico de tumores solidos - Google Patents

Marcadores farmacogenomicos para el pronostico de tumores solidos

Info

Publication number
CR9298A
CR9298A CR9298A CR9298A CR9298A CR 9298 A CR9298 A CR 9298A CR 9298 A CR9298 A CR 9298A CR 9298 A CR9298 A CR 9298A CR 9298 A CR9298 A CR 9298A
Authority
CR
Costa Rica
Prior art keywords
solid tumors
forecast
pharmacogenomic markers
patients
present
Prior art date
Application number
CR9298A
Other languages
English (en)
Inventor
Michael E Burczynski
Frederick Immermann
Andrew Strahs
Natalie C Twine
Donna Slonim
William L Trepicchio
Andrew Dorne
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9298A publication Critical patent/CR9298A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion suministra metodos, sistemas y equipo para el pronostico o evaluacion de tratamiento de tumores solidos. Los marcadores geneticos que son pronosticos de tumores solidos se pueden identificar de acuerdo con la presente invencion. El marcador de cada gen tiene patrones de expresion alterados en PBMC de los pacientes con tumor solido luego de la iniciacion de un tratamiento antineoplasico, y la magnitud de estas alteraciones se correlaciona con los resultados clinicos de estos pacientes.
CR9298A 2005-02-18 2007-08-08 Marcadores farmacogenomicos para el pronostico de tumores solidos CR9298A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65408205P 2005-02-18 2005-02-18

Publications (1)

Publication Number Publication Date
CR9298A true CR9298A (es) 2007-11-23

Family

ID=36649050

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9298A CR9298A (es) 2005-02-18 2007-08-08 Marcadores farmacogenomicos para el pronostico de tumores solidos

Country Status (15)

Country Link
US (1) US20090061423A1 (es)
EP (1) EP1849007A2 (es)
JP (1) JP2008529554A (es)
KR (1) KR20070115891A (es)
CN (1) CN101120255A (es)
AU (1) AU2006214078A1 (es)
BR (1) BRPI0608429A2 (es)
CA (1) CA2598393A1 (es)
CR (1) CR9298A (es)
IL (1) IL185206A0 (es)
MX (1) MX2007010001A (es)
NO (1) NO20074065L (es)
RU (1) RU2007129864A (es)
WO (1) WO2006089185A2 (es)
ZA (1) ZA200706919B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435529B2 (ja) * 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
US20100222230A1 (en) * 2007-04-11 2010-09-02 The General Hospital Corporation Diagnostic and prognostic methods for renal cell carcinoma
NZ600268A (en) * 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX369911B (es) 2013-05-30 2019-11-26 Genomic Health Inc Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
JP6427750B2 (ja) * 2013-10-02 2018-11-28 コニカミノルタ株式会社 Ｃｘｃｌ１、ならびにｓｍｏｘおよび／またはｉｄ１の発現量に基づく肺癌患者の予後を判定するためのデータ収集方法およびキット
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
US20180100859A1 (en) * 2015-03-24 2018-04-12 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CN111537424B (zh) * 2020-04-26 2022-10-28 北京市神经外科研究所 基于外周血细胞评估脊髓胶质瘤患者预后性的系统
CN111640518A (zh) * 2020-06-02 2020-09-08 山东大学齐鲁医院 一种宫颈癌术后生存预测方法、系统、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076735A1 (en) * 1998-09-25 2002-06-20 Williams Lewis T. Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
WO2002061144A2 (en) * 2001-01-31 2002-08-08 Whitehead Institute For Biomedical Research Brain tumor diagnosis and outcome prediction
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors

Also Published As

Publication number Publication date
IL185206A0 (en) 2008-01-06
US20090061423A1 (en) 2009-03-05
CA2598393A1 (en) 2006-08-24
CN101120255A (zh) 2008-02-06
WO2006089185A8 (en) 2007-09-27
JP2008529554A (ja) 2008-08-07
ZA200706919B (en) 2008-06-25
WO2006089185A3 (en) 2006-09-28
EP1849007A2 (en) 2007-10-31
KR20070115891A (ko) 2007-12-06
RU2007129864A (ru) 2009-03-27
MX2007010001A (es) 2007-09-27
BRPI0608429A2 (pt) 2009-12-29
WO2006089185A2 (en) 2006-08-24
AU2006214078A1 (en) 2006-08-24
NO20074065L (no) 2007-11-14

Similar Documents

Publication Publication Date Title
CR9298A (es) Marcadores farmacogenomicos para el pronostico de tumores solidos
WO2019195268A3 (en) Methylation markers and targeted methylation probe panels
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
CR9100A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
MX2018009804A (es) Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
CL2024000856A1 (es) Composiciones de oligonucleótidos y métodos de estas
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
WO2009108917A3 (en) Markers for improved detection of breast cancer
CL2004000700A1 (es) Metodo para detectar el estado de un cancer correctal que comprende identificar la modulacion diferencial de cada gen en una combinacion de genes seleccionados de seq id 1,2,3 y 4.
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
WO2012129488A3 (en) Gene signatures associated with rejection or recurrence of cancer
WO2011027310A8 (en) Novel tumor markers
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
WO2008037700A3 (en) Methods for breast cancer prognosis
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
BRPI0515319A (pt) análogos de quinolona
MX339340B (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX381948B (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)